Search the Newsreel

OABI Earning Date, Earning Analysis and Earning Prediction

This article provides an analysis and prediction of OABI's earnings, focusing on past results, analyst forecasts for 2026/Q3, and the correlation between earning revisions and stock price movements. It details OABI's recent earnings reports, including revenue and EPS surprises, and discusses the typical stock …

New Forecasts: Here's What Analysts Think The Future Holds For OmniAb, Inc. (NASDAQ:OABI)

Analysts have significantly upgraded their statutory estimates for OmniAb, Inc. (OABI), increasing revenue forecasts and reducing expected losses for 2026. Despite the positive adjustments, the company is still projected to experience a revenue decline faster than the broader industry, although the reduced loss estimates …

HC Wainwright Forecasts OmniAb's Q3 Earnings (NASDAQ:OABI)

Price to sales forward of OmniAb, Inc. – NASDAQ:OABIW

This article provides the "Price to sales forward" metric for OmniAb, Inc. (NASDAQ: OABIW), a company listed on the Nasdaq Stock Market. The content appears to be a financial data snippet from a platform like TradingView, showing the period, value, and change for this …

OmniAb (NASDAQ:OABI) Issues Quarterly Earnings Results, Beats Expectations By $0.07 EPS

OmniAb (NASDAQ:OABI) reported its quarterly earnings, beating analyst expectations with an adjusted loss of $0.05 per share against an estimated $0.12 loss, and revenues of $13.41 million significantly surpassing estimates of $4.69 million. The company's Q2 revenue increased year-over-year, and its net loss narrowed, …

OmniAb, Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:OABI) 2026-08-07

OmniAb, Inc. (OABI) has released its Q2 2026 earnings call presentation. The company reported an EPS of -$0.05, which beat estimates by $0.08, and revenue of $13.42 million, exceeding expectations by $8.72 million and representing a 244.24% year-over-year increase. The slide deck provides details …

OmniAb, Inc. 1H 2026: Revenue $27.8M, EPS ($0.05) — 10-Q Summary

OmniAb, Inc. (OABI) reported a significant increase in revenue for the first half of 2026, reaching $27.8 million, up from $3.9 million in the prior comparable period. This growth was primarily driven by license and milestone receipts. Despite remaining net loss-making, the diluted loss …

OmniAb Reports Second Quarter 2026 Financial Results and Business Highlights

OmniAb, Inc. reported strong second-quarter 2026 financial results, with revenue significantly increasing to $13.4 million, driven by milestone revenue and growth in xPloration. The company raised its full-year 2026 revenue and cash outlook, expecting revenue between $32 million and $36 million. OmniAb also highlighted …

OmniAb Inc (OABI) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of OmniAb Inc (OABI), detailing its current price momentum, support and resistance levels, and various technical indicator readings. The stock is currently trading between a resistance level of 2.43 and a support level of 1.98, suggesting suitability for …

OmniAb Inc (OABI) (Q2 2026) Earnings Call Highlights: Revenue Surges 243% as Two Programs Leap ...

OmniAb Inc (OABI) reported strong Q2 2026 results with a 243% revenue surge to $13.4 million, driven by higher milestone revenue and two programs advancing directly from Phase 1 to Phase 3. The company, which uses a unique transgenic chicken platform for human antibody …

OmniAb, Inc. (OABI) Reports Q2 Loss, Beats Revenue Estimates

OmniAb, Inc. (OABI) reported a Q2 loss of $0.05 per share, surpassing the Zacks Consensus Estimate of a $0.11 loss and significantly improving from a $0.15 loss a year ago. The company also

OmniAb Q2 2026 slides: revenue surges 244%, guidance raised

OmniAb Inc. (NASDAQ:OABI) reported a significant 244% year-over-year revenue increase in Q2 2026, reaching $13.4 million, primarily driven by milestone payments and the xPloration instrument platform. This strong performance led the company to raise its full-year 2026 revenue guidance to $32 million to $36 …

OmniAb (NASDAQ: OABI) grows partner base and cuts cash burn in 2026

OmniAb Inc. reported a significant increase in revenue for Q2 and H1 2026, driven by license and milestone payments, while simultaneously reducing its net loss and cash burn from operations. The company expanded its partner base to 110 active partners and 425 active programs, …

OmniAb (NASDAQ: OABI) boosts 2026 revenue guidance after strong Q2

OmniAb (NASDAQ: OABI) reported strong Q2 2026 results, with revenue reaching $13.4 million, significantly up from $3.9 million in Q2 2025, driven by milestone, service, and xPloration sales. The company narrowed its net loss to $5.9 million and raised its full-year 2026 revenue guidance …

OmniAb (OABI) Earnings Date and Reports 2026

OmniAb Inc (OABI) Earnings Forecast: Future EPS & Revenue Growth Estimates

Earnings To Watch: OmniAb Inc (OABI) Q2 2026 -- GF Value Sees 54% Upside

OmniAb (NASDAQ: OABI) awards 800,000 stock options to its COO

OmniAb, Inc. (NASDAQ: OABI) has granted its Chief Operating Officer, Nwachuku Amechi Ekeke, 800,000 stock options with an exercise price of $1.98 per share, expiring on August 1, 2036. The options will vest over 42 months, beginning August 1, 2026, contingent on Ekeke's continued …

OABIW Stock Warrant Price and Chart — NASDAQ:OABIW

This page provides an overview of OmniAb, Inc. (OABIW) stock warrant, including its market capitalization of $294.29 million, key financial figures like net income and revenue, and company details. OmniAb, Inc. is a drug discovery company specializing in human monoclonal and bispecific therapeutic antibodies, …

Number of shareholders of OmniAb, Inc. – NASDAQ:OABI

This article states that OmniAb, Inc. (NASDAQ: OABI) has "No trades" and provides general information about the company's financials, news, and community on the TradingView platform. It appears to be a stub or an incomplete page that only lists the company and market information, …

Enterprise value to revenue forward of OmniAb, Inc. – BOATS:OABI

This article provides an "Enterprise value to revenue forward" metric for OmniAb, Inc. (BOATS:OABI) on TradingView. It appears to be a financial data point rather than an in-depth analysis, presented within the platform's interface. The content primarily consists of navigation and boilerplate information from …

OmniAb Inc (OABI) Institutional Confidence

The article analyzes the institutional confidence in OmniAb Inc (OABI), noting its current institutional shareholding score of 5.00, placing it 132nd within the Biotechnology & Medical Research industry. Institutional shareholding has increased by 3.41% quarter-over-quarter, reaching 57.16%, with Bill Nygren | OAKMX being the …

OmniAb, Inc. Revenue Breakdown – NASDAQ:OABIW

OmniAb, Inc. (NASDAQ:OABIW) generated $18.67 million in revenue last year, with its top-performing segment, License and Milestone, contributing $9.77 million. This is a decrease from $13.87 million in the previous year for the same segment. The United States was the primary source of revenue, …

OmniAb (OABI) to Post Earnings on Thursday

OABI|OmniAb Inc|Price:1.950|

This article provides a comprehensive analysis of OmniAb Inc (OABI) through its "TradingKey Stock Score." The company shows healthy fundamentals, high growth potential, and is considered fairly valued within the Biotechnology & Medical Research industry. Analysts have rated OABI as a "Buy" with a …

Price to earnings forward of OmniAb, Inc. – NASDAQ:OABI

This article provides a financial overview of OmniAb, Inc. (NASDAQ: OABI), specifically focusing on its forward price-to-earnings ratio. The content appears to be a stub or a section of a larger financial data page on TradingView, indicating that the detailed financial data for this …

OABI|OmniAb Inc|Price:1.950|Chg%:-0.020

This article provides a comprehensive analysis of OmniAb Inc (OABI) through its "TradingKey Stock Score." The company shows healthy fundamentals, high growth potential, and is considered fairly valued within the Biotechnology & Medical Research industry. Analysts have rated OABI as a "Buy" with a …

Enterprise value to EBIT forward of OmniAb, Inc. – NASDAQ:OABI

This article focuses on the enterprise value to EBIT forward for OmniAb, Inc. (NASDAQ:OABI). It indicates that financial data for this metric is provided by FactSet Research Systems Inc. and market data by ICE Data Services.

Veraxa Advances Bispecific ADC Candidate VXA-222 Following OmniAb Discovery Milestone

Veraxa Biotech has advanced its bispecific antibody-drug conjugate (ADC) program, VXA-222, into the next development phase after OmniAb completed its antibody discovery work. This collaboration utilizes OmniAb's transgenic antibody discovery platform and Veraxa’s proprietary ADC linker and conjugation technology to create a dual-antigen "AND-gate" …

VERAXA Biotech (NASDAQ: VRXA) Advances Bispecific ADC Program Under OmniAb Collaboration

VERAXA Biotech (NASDAQ: VRXA) has advanced its bispecific antibody-drug conjugate (bsADC) program, VXA-222, reaching a key technical milestone in its collaboration with OmniAb (NASDAQ: OABI). OmniAb completed its discovery work, moving the program to its next phase. VXA-222 is designed to target two tumor …

OABI|OmniAb Inc|Price:2.030|

OmniAb Inc. (OABI) licenses discovery research technology to pharmaceutical and biotech companies, leveraging its OmniAb platform to identify optimal antibodies for drug development. The company utilizes engineered transgenic animals like OmniRat and OmniChicken to generate human sequence antibodies. OmniAb's top five shareholders include Mr. …

Veraxa advances cancer therapy program with OmniAb

Veraxa Biotech AG announced that its bispecific antibody-drug conjugate program, VXA-222, advanced to the next development phase after completing discovery work with OmniAb, Inc. The program targets solid tumors using AND-gate logic, combining OmniAb's antibody discovery technologies with Veraxa's linker technology. Veraxa holds exclusive …

VERAXA Biotech Announces Advancement of Novel Bispecific Antibody Drug Conjugate Program VXA-222 from Joint Discovery Collaboration with OmniAb

VERAXA Biotech announced the advancement of its bispecific ADC (bsADC) program VXA-222, developed in collaboration with OmniAb. This program, which uses an "AND-gate" logic to target solid tumors, has moved into its next phase following the successful completion of OmniAb's discovery work. VERAXA will …